JMJD6 is described in the source as an iron (Fe2+)- and α-ketoglutarate (2-OG)-dependent dioxygenase that exhibits multiple enzymatic activities. As a key regulator of epigenetic modification and post-transcriptional regulation, JMJD6 has been observed to be frequently overexpressed in a variety of malignancies. The review frames JMJD6 as a multifunctional enzyme that connects intrinsic tumor cell programs with extrinsic influences from the tumor microenvironment.
The authors emphasize JMJD6’s enzymatic versatility as central to its biological effects in cancer. Because JMJD6 participates in both chromatin-associated and RNA-related processes, its activity can alter gene expression programs and cellular phenotypes relevant to carcinogenesis.
The review systematically examines how JMJD6 contributes to canonical oncogenic behaviors. JMJD6 is reported to directly promote tumor cell proliferation, invasion, and metastasis, and to support maintenance of tumor stemness. Two mechanistic examples highlighted are p53 hydroxylation, which negatively regulates p53 tumor-suppressor function, and activation of the β-catenin/c-Myc signaling pathway, which links JMJD6 to proliferative and transformation-promoting transcriptional programs.
By engaging these pathways, JMJD6 is positioned as a direct facilitator of tumor progression through modulation of both tumor suppressor activity and pro-oncogenic signaling cascades.
Beyond tumor cell–intrinsic roles, the source emphasizes JMJD6’s capacity to shape an immunosuppressive tumor microenvironment that facilitates immune evasion. A specific mechanism discussed is JMJD6-driven polarization of tumor-associated macrophages toward an M2 phenotype via the STAT3/IL-10 axis. Such macrophage polarization is presented as an example of how JMJD6 activity in the tumor milieu can suppress anti-tumor immunity and promote conditions favorable to tumor growth.
The review frames JMJD6 as an integrative node that links intracellular oncogenic programs with extracellular immune-regulatory processes, thereby amplifying tumor-promoting effects through both cell-autonomous and non–cell-autonomous mechanisms.
Because JMJD6 is frequently overexpressed in malignancies and correlates with poorer clinical outcomes, the authors identify JMJD6 as a promising prognostic biomarker. The review highlights the potential utility of measuring JMJD6 expression or activity to stratify risk or prognosis, though details on specific clinical assays or validation cohorts are not provided in the abstract.
Overall, JMJD6’s dual roles in promoting intrinsic tumor aggressiveness and extrinsic immune suppression underpin its proposed value as a biomarker that reflects both tumor biology and immune-contexture.
Given its central contributions to oncogenesis and immune evasion, JMJD6 is discussed as a viable therapeutic target. The review summarizes recent advances in the development of JMJD6-targeted small-molecule inhibitors, noting these agents and strategies are at a preclinical or experimental stage according to the source.
One therapeutic concept highlighted is combining JMJD6 inhibition with immune checkpoint inhibitors to simultaneously reverse tumor-intrinsic drivers and relieve tumor-mediated immune suppression. The authors describe this combined approach as promising but still experimental, and they call for further investigation to establish safety, efficacy, and optimal implementation.
The review acknowledges current challenges to translating JMJD6-targeted strategies into clinical practice. While the abstract does not enumerate specific technical or translational hurdles, it states that issues remain that warrant further study and discussion. The authors summarize recent progress but emphasize that clinical translation will require additional preclinical validation and careful exploration of combination regimens, dosing, and biomarker-guided patient selection.
The review also discusses future directions for research aimed at clarifying JMJD6’s mechanistic roles across tumor types and at advancing candidate inhibitors toward clinical testing.
In the authors’ synthesis, JMJD6 is a multifunctional epigenetic and post-transcriptional regulator that promotes tumor progression and cultivates an immunosuppressive microenvironment. Its actions—illustrated by p53 hydroxylation, β-catenin/c-Myc activation, and promotion of M2 macrophage polarization via STAT3/IL-10—position JMJD6 as both a prognostic biomarker and a candidate therapeutic target. Targeting JMJD6, particularly in combination with immune checkpoint blockade, is presented as a compelling but still experimental therapeutic prospect that requires further investigation and clinical translation efforts.
Conflict of interest: the authors declare no competing interests, as reported in the source.